Our pipeline of immune-modulating, clinical-stage product candidates are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation.

Program & Target Therapeutic Area Preclinical Phase 1 Phase 2 Phase 3 Mkt Rights
Rilonacept* IL-1α & IL-1β Recurrent Pericarditis** End Phase 3
Worldwide (excluding the Middle East and North Africa)
Mavrilimumab*** GM-CSFRα Giant Cell Arteritis Phase 2
COVID-19 Pneumonia & Hyperinflammation Phase 2
Vixarelimab OSMRβ Prurigo Nodularis Phase 2
Diseases Characterized by Chronic Pruritus Phase 2
KPL-404 CD40 T-Cell Dependent, B-Cell–Mediated Indications Phase 1
*The FDA granted Breakthrough Therapy designation to rilonacept for recurrent pericarditis in 2019 and Orphan Drug designation to rilonacept for pericarditis in 2020.
**Data from RHAPSODY, a pivotal Phase 3 trial of rilonacept in recurrent pericarditis, were reported in June 2020. Per the license agreement with Regeneron Pharmaceuticals, Inc, ownership of the rilonacept BLA will transfer to Kiniksa. Kiniksa expects to file an sBLA with the FDA by the end of 2020.
*** The FDA granted Orphan Drug designation to mavrilimumab for giant cell arteritis in 2020.

Every Second Counts!